伊立替康个体化治疗:药代动力学、药效学与药物基因组学综述
伊立替康自1998年上市以来广泛用于结直肠癌、胰腺癌和肺癌等实体瘤,但其剂量限制性毒性和大的个体间药代动力学变异突出。该药经羧酸酯酶水解为活性代谢物SN-38,后者活性比母药强100至1000倍,多种I相和II相酶参与其代谢,使代谢易受环境和遗传因素影响。本综述更新了伊立替康药代动力学、药效学和药物基因组学文献,指出基因变异、患者特征、生活方式和合并用药均影响其药代动力学,需要更个体化的给药策略。
要点
- 伊立替康活性代谢物SN-38活性比母药强100至1000倍。
- CYP3A4和UGT1A等酶参与伊立替康代谢,基因变异可部分预测毒性和疗效。
- 患者特征、生活方式和合并用药也影响伊立替康药代动力学。
核心结论
- 伊立替康药代动力学个体间变异大,需基于药代动力学、药效学和药物基因组学制定个体化给药策略以预防过度毒性并优化疗效。
主要发现
- 伊立替康经羧酸酯酶水解为活性代谢物SN-38,其活性比伊立替康本身强100至1000倍。
- CYP3A4和UGT1A等I相和II相酶参与伊立替康无活性代谢物的形成,使其代谢易受环境和遗传因素影响。
- retrospective和前瞻性试验及荟萃分析显示,酶和转运蛋白的基因变异可部分预测伊立替康相关毒性和疗效。
- 患者特征、生活方式和合并用药也影响伊立替康药代动力学,饮食限制等其他因素正在研究中。
关键数值与推荐
- SN-38活性比伊立替康强100至1000倍。
临床怎么用
- 临床应关注影响伊立替康药代动力学的患者特征、生活方式和合并用药,并考虑基因变异对毒性和疗效的预测作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokinetic variability. Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 1000-fold more active compared with irinotecan itself. Several phase I and II enzymes, including cytochrome P450 (CYP) 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A, are involved in the formation of inactive metabolites, making its metabolism prone to environmental and genetic influences. Genetic variants in the DNA of these enzymes and transporters could predict a part of the drug-related toxicity and efficacy of treatment, which has been shown in retrospective and prospective trials and meta-analyses. Patient characteristics, lifestyle and comedication also influence irinotecan pharmacokinetics. Other factors, including dietary restriction, are currently being studied. Meanwhile, a more tailored approach to prevent excessive toxicity and optimize efficacy is warranted. This review provides an updated overview on today's literature on irinotecan pharmacokinetics, pharmacodynamics, and pharmacogenetics.
引用
- de Man FM, Goey AKL, van Schaik RHN, et al. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018. PMID: 29520731. doi:10.1007/s40262-018-0644-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。